The Hydropothecary Corp. is one of the best cannabis plays for investors, Echelon Wealth says

The Hydropothecary Corp. (The Hydropothecary Corp. Stock Quote, Chart, News: TSXV:THCX) is uniquely positioned as a low cost producer with strong value-added product capabilities, Echelon Wealth Partners analyst Russell Stanley says.

In a research report to clients today, Stanley initiated coverage of THCX with a “Speculative Buy” rating and a one-year price target of $5.50, implying a return of 40 per cent at the time of publication.

Stanley says Gatineau based Hydropothecary has what it takes to succeed in the nascent but already competitive sector.

“We expect the forthcoming dramatic increase in the industry’s cultivation capacity to commoditize dried cannabis production,” the analyst says. “In combination with government owned, centralized distribution models in Canada’s core recreational markets, many producers will struggle in an increasingly competitive environment. We believe the best plays for investors are companies with ultra-low cost production capability and/or demonstrated strength in developing and commercializing value-added products. Based on cash costs of finished goods inventory, THCX has reduced its product cost to $0.89/gram as of last quarter, down from $1.79/gram y/y. The Company also generates 40%+ of its revenue from value-added products, two of which won first and third place, respectively, at Lift’s Canadian Cannabis Awards in November 2017. We understand that vape pens, prerolls, and topicals are priorities for product development.”

Stanley thinks THCX will generate Adjusted EBITDA of negative $12.8-million on revenue of $11.4-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $15.0-million on a topline of $97.1-million the following year.

“Our central thesis continues to be that increasing supply and centralized purchasing by government-owned distributors in core markets will pressure pricing for dried cannabis over time,” Stanley adds. “From the government’s perspective, squeezing out the illicit market requires low pricing, without pricing product so low that it effectively encourages cannabis use.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: thcx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Uber stock a buy? (May, 2024)

Following the release of the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on… [Read More]

2 days ago

Trulieve scores price target raise at Echelon

Following the company's most recent results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Trulieve Cannabis… [Read More]

2 days ago

Is Green Thumb Industries a buy? (May, 2024)

Its first quarter numbers are in the books and Beacon Securities analyst Russell Stanley is still bullish on Green Thumb… [Read More]

3 days ago

Is TKO stock a buy?

Following the company's first quarter results, Roth MKM analyst Eric Handler has maintained his "Buy" rating on TKO Group (TKO… [Read More]

3 days ago

Is WELL Health stock a buy? (May, 2024)

Following the company's first quarter results, Eight Capital analyst Christian Sgro thinks there is a lot of money to be… [Read More]

3 days ago

“You Never Get Fired for Buying Shopify”

Its first quarter results are in the books and ATB Capital Markets analyst Martin Toner has become bullish on Shopify… [Read More]

3 days ago